News >

Expert Shares Excitement Over Biosimilars in Oncology

Angelica Welch
Published: Tuesday, Mar 20, 2018

Sunil Verma, MD

Sunil Verma, MD
ABP-215 (bevacizumab-awwb; Mvasi), a biosimilar for bevacizumab (Avastin), was approved by the FDA In September 2017 for the treatment of adult patients with colorectal, lung, brain, kidney, and cervical cancers. This was the first approval of a biosimilar in the United States for the treatment of patients with cancer.

, Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, shared his insight on the approval of MYL-1401O, as well as his excitement for the future development of biosimilars across oncology.

OncLive: Can you discuss the background of the recently FDA-approved trastuzumab biosimilar?

Verma: We are in a very interesting framework in breast cancer and in oncology at large. We must ensure that we are able to provide effective therapies, but the costs associated with these treatments are substantial. In order for us to incorporate innovation and new therapies, we need to make sure that we also transition some of our old biologics and incorporate biosimilars.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Community Practice Connections™: Show Me the Data™: Leveraging the Evidence to Optimize Applications of Biosimilars in CancerAug 30, 20201.5
Publication Bottom Border
Border Publication
x